Role of the Subarachnoid Hemorrhage Early Brain Edema Score in the Management of Decompressive Craniectomy for Poor-Grade Aneurysmal Subarachnoid Hemorrhage.


Journal

World neurosurgery
ISSN: 1878-8769
Titre abrégé: World Neurosurg
Pays: United States
ID NLM: 101528275

Informations de publication

Date de publication:
10 2022
Historique:
received: 04 06 2022
revised: 28 06 2022
accepted: 29 06 2022
pubmed: 9 7 2022
medline: 6 10 2022
entrez: 8 7 2022
Statut: ppublish

Résumé

The Subarachnoid Hemorrhage Early Brain Edema Score (SEBES) is a radiographic marker for early brain injury after aneurysmal subarachnoid hemorrhage (aSAH). We evaluated the role of the SEBES in performing decompressive craniectomy (DC) for poor-grade aSAH. We retrospectively analyzed all cases of poor-grade (World Federation of Neurosurgical Societies [WFNS] grade IV and V) aSAH in adults who underwent microsurgery at our center between April 2017 and March 2021. Patient demographics, clinical presentation, imaging findings, and surgical data were obtained. The study endpoints of DC rate, complications, and functional outcomes (modified Rankin Scale score >3) were compared between the traditional surgery and SEBES-informed groups. A survival analysis was performed to estimate 180-day survival and hazard ratios for death. The study included 116 patients (mean age, 60.8 ± 9.5 years, DCs [n = 63, 54.3%]). In the univariate analysis, age, intracranial pressure, midline shift, pupil changes, SEBES grade III-IV, traditional group, and WFNS grade Ⅴ were associated with DC. DC (46.4% vs. 67.4%) and in-hospital mortality rates (9.6% vs. 25.6%) were significantly lower in the SEBES-informed group. At day 180 after admission, modified Rankin Scale scores did not significantly differ between the 2 groups, but 180-day survival was significantly higher in the SEBES-informed group (78.1% vs. 53.5%). In the multivariable analysis, age, pupil changes, being in the traditional group, and delayed cerebral ischemia were independently associated with 180-day postadmission mortality. The SEBES provides good imaging support for preoperative and intraoperative intracranial pressure management in poor-grade aSAH, allowing for improved DC-related decision-making and better 180-day survival.

Sections du résumé

BACKGROUND
The Subarachnoid Hemorrhage Early Brain Edema Score (SEBES) is a radiographic marker for early brain injury after aneurysmal subarachnoid hemorrhage (aSAH). We evaluated the role of the SEBES in performing decompressive craniectomy (DC) for poor-grade aSAH.
METHODS
We retrospectively analyzed all cases of poor-grade (World Federation of Neurosurgical Societies [WFNS] grade IV and V) aSAH in adults who underwent microsurgery at our center between April 2017 and March 2021. Patient demographics, clinical presentation, imaging findings, and surgical data were obtained. The study endpoints of DC rate, complications, and functional outcomes (modified Rankin Scale score >3) were compared between the traditional surgery and SEBES-informed groups. A survival analysis was performed to estimate 180-day survival and hazard ratios for death.
RESULTS
The study included 116 patients (mean age, 60.8 ± 9.5 years, DCs [n = 63, 54.3%]). In the univariate analysis, age, intracranial pressure, midline shift, pupil changes, SEBES grade III-IV, traditional group, and WFNS grade Ⅴ were associated with DC. DC (46.4% vs. 67.4%) and in-hospital mortality rates (9.6% vs. 25.6%) were significantly lower in the SEBES-informed group. At day 180 after admission, modified Rankin Scale scores did not significantly differ between the 2 groups, but 180-day survival was significantly higher in the SEBES-informed group (78.1% vs. 53.5%). In the multivariable analysis, age, pupil changes, being in the traditional group, and delayed cerebral ischemia were independently associated with 180-day postadmission mortality.
CONCLUSIONS
The SEBES provides good imaging support for preoperative and intraoperative intracranial pressure management in poor-grade aSAH, allowing for improved DC-related decision-making and better 180-day survival.

Identifiants

pubmed: 35803571
pii: S1878-8750(22)00931-7
doi: 10.1016/j.wneu.2022.06.147
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e245-e252

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Yong-Hong Duan (YH)

Hengyang Key Laboratory of Hemorrhagic Cerebrovascular Disease, Department of Neurosurgery, The Second Affiliated Hospital, Hengyang Medical School University of South China, Hengyang, Hunan, China.

Jian He (J)

Hengyang Key Laboratory of Hemorrhagic Cerebrovascular Disease, Department of Neurosurgery, The Second Affiliated Hospital, Hengyang Medical School University of South China, Hengyang, Hunan, China.

Xiao-Fei Liu (XF)

Hengyang Key Laboratory of Hemorrhagic Cerebrovascular Disease, Department of Neurosurgery, The Second Affiliated Hospital, Hengyang Medical School University of South China, Hengyang, Hunan, China.

Yuan-Ding Jiang (YD)

Hengyang Key Laboratory of Hemorrhagic Cerebrovascular Disease, Department of Neurosurgery, The Second Affiliated Hospital, Hengyang Medical School University of South China, Hengyang, Hunan, China.

Tao Wang (T)

Hengyang Key Laboratory of Hemorrhagic Cerebrovascular Disease, Department of Neurosurgery, The Second Affiliated Hospital, Hengyang Medical School University of South China, Hengyang, Hunan, China.

Jie Luo (J)

Hengyang Key Laboratory of Hemorrhagic Cerebrovascular Disease, Department of Neurosurgery, The Second Affiliated Hospital, Hengyang Medical School University of South China, Hengyang, Hunan, China.

Peng Xu (P)

Hengyang Key Laboratory of Hemorrhagic Cerebrovascular Disease, Department of Neurosurgery, The Second Affiliated Hospital, Hengyang Medical School University of South China, Hengyang, Hunan, China.

Yong-Dong Li (YD)

Hengyang Key Laboratory of Hemorrhagic Cerebrovascular Disease, Department of Neurosurgery, The Second Affiliated Hospital, Hengyang Medical School University of South China, Hengyang, Hunan, China.

Zhen-Kun Xiao (ZK)

Hengyang Key Laboratory of Hemorrhagic Cerebrovascular Disease, Department of Neurosurgery, The Second Affiliated Hospital, Hengyang Medical School University of South China, Hengyang, Hunan, China.

Aihua Liu (A)

Beijing Neurosurgical Institute, Capital Medical University, Beijing, China; Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Beijing, China.

Fei Peng (F)

Beijing Neurosurgical Institute, Capital Medical University, Beijing, China; Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Beijing, China.

Yong-Mei Yang (YM)

Department of Anatomy, Hengyang Medical School University of South China, Hengyang, Hunan, China. Electronic address: yangym-nhu@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH